Ansbert K. Gadicke, M.D.Dr. Ansbert Gadicke is the Founder and a Managing Director of the MPM Group. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. MPM Capital is one of the world's largest dedicated investors in life sciences. With committed capital under active management of $2.5 billion, MPM is uniquely structured to invest globally in healthcare innovation. In addition to its BioVentures family of venture capital funds, MPM invests in the public markets through its BioEquities hedge fund. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell. Dr. Gadicke is a Director of Cerimon Pharmaceuticals; Elixir Pharmaceuticals; JapanBridge Pharmaceuticals, Tokyo; Radius Pharmaceuticals; and Xanodyne Pharmaceuticals. He previously served as a Director of Arriva, BioMarin (NASDAQ:BMRN); Biovitrum (Stockholm:BVT); Chiasma, Inc.; Coelacanth; Idenix (NASDAQ:IDIX); Kourion; MediGene (Frankfurt:MDG); Omrix Biopharmaceuticals (NASDAQ:OMRI); Pharmasset, Inc.; PharmAthene (AMEX:PIP); Transform; and ViaCell (NASDAQ:VIAC). He is a member of the Advisory Council for Harvard Medical School.
|
|
